Blogs
Best of 2022: Methotrexate in PsA
Until the publication of the SEAM trial, evidence in the medical literature for the efficacy of the most commonly used drug for psoriatic arthritis worldwide, methotrexate, has been lukewarm at best. Yet we all employ it commonly, either as monotherapy or in combination with biologic or targeted synthetic DMARD treatment. It is inexpensive and widely available, and only modestly toxic.
A Domain-Based Approach to the GRAPPA Psoriatic Arthritis Treatment Recommendations
With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.
The Contribution of the Gut Microbiome and Diet to Joint Inflammation in PsA
Interactions of the gut microbiota in humans promote the release of a variety of metabolites with profound effects on human health and immune regulation.
Methotrexate in PsA
Until the publication of the SEAM trial, evidence in the medical literature for the efficacy of the most commonly used drug for psoriatic arthritis worldwide, methotrexate, has been lukewarm at best. Yet we all employ it commonly, either as monotherapy or in combination with biologic or targeted synthetic DMARD treatment. It is inexpensive and widely available, and only modestly toxic.
Guiding Patients Considering Biologics
What are the questions patients should ask their doctors about biologics? Are there rules for starting and stopping biologics?
KOLs Predict: What Will the Next Year Bring?
A new subspecialty may emerge. New drugs will be approved (but it will be difficult for patients to get coverage for them). And an American team will win the World Series. All these and more: here are predictions for 2017 and beyond from rheumatologists across the country and around the world.
Dress Syndrome – A Diagnostic and Management Nightmare
The DRESS syndrome is a rare and sometimes catastrophic disorder resulting from specific drug exposures, including allopurinol, minocycline, INH, anticonvulsants or retroviral agents.
Hot Stuff from the Cleveland Clinic Biologic Therapies Summit – Part I
Highlights and take-home messages from the Cleveland Clinic Center for Continuing Education's Biologic Therapies Summit held this week (April 30 – May 2, 2015).